Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Hormonal · Dosing reference

Kisspeptin-54 dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyBLimited human dataNone established
Full research pageCycle-length evidenceComparePrefer Amiravo on Google
Regulatory status
Not approved — research use only
Human amounts
None established in humans
Route studied
Studied intravenously, subcutaneously and intranasally in research settings
Frequency
Not established
Half-life
About 28 minutes (intravenous, healthy men)
Evidence grade
Grade B · Limited human data
Vial sizes on the market
Not recorded
Other forms seen
—

What Kisspeptin-54 is

Kisspeptin-54 (metastin) is the 54-amino-acid form of the hypothalamic peptide kisspeptin, which acts on the KISS1R (GPR54) receptor to drive GnRH and downstream LH and FSH release. Academic human studies have given it intravenously, subcutaneously and intranasally to healthy volunteers, women with hypothalamic amenorrhoea and women undergoing IVF, where it was used to trigger oocyte maturation. It is not approved for any use and is prohibited in sport; this entry summarizes the published studies for research reference only.

Kisspeptin is the endogenous ligand of the G protein-coupled receptor KISS1R (GPR54); inactivating mutations of this pathway are associated with failure of reproductive function and infertility 1,5. Neuroendocrine action Kisspeptin acts at the hypothalamus to release an endogenous pool of GnRH, which in turn drives pituitary LH and FSH secretion 7. In humans, raising circulating kisspeptin-54 increased LH, FSH… How it works →

Key evidence

  • Dhillo et al., J Clin Endocrinol Metab · 2005 · Humans (healthy men, n=6)
    Kisspeptin-54 increased mean LH (10.8 vs 4.2 U/L), FSH and testosterone versus saline; plasma half-life was 27.6 minutes 1. 1
  • Dhillo et al., J Clin Endocrinol Metab · 2007 · Humans (healthy women with regular cycles)
    LH rose dose-dependently; the response was greatest in the preovulatory phase (mean increase 20.64 IU/L) and smallest in the follicular phase (0.12 IU/L) 2. 2
  • Jayasena et al., J Clin Endocrinol Metab · 2009 · Humans (women with hypothalamic amenorrhoea, n=10)
    LH and FSH rose markedly on day 1 but responses were significantly reduced by day 14, indicating desensitization; GnRH responsiveness was preserved 3. 3
All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered Kisspeptin-54. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

  • Human studies ranged from single-session infusions to 2 weeks of repeated administration 1,3.
  • Follicular-phase exposure over 1 week in healthy women 4.
Cycle-length evidence for Kisspeptin-54

Who was excluded from the studies

  • No label exists, so no formal contraindications are defined 9.

Side effects reported in studies

  • Moderate ovarian hyperstimulation syndrome
    1 of 31 (3.2%) single trigger vs 0 of 31 with additional administration · Women at high risk of OHSS undergoing IVF 7
  • Moderate, severe or critical OHSS
    0 of 60 · Women at high risk of OHSS undergoing IVF 6
  • Any side effect or adverse event (intranasal)
    None encountered · Healthy men and women and women with hypothalamic amenorrhoea 8
Full adverse-event data

Kisspeptin-54 draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength
2 · Water added
3 · Amount per draw
4 · Syringe
Your mix
10 mg + 2 mL water = 5 mg/mL
10 units holds 0.5 mg (500 mcg)
Draw toEnter an amount in step 3
0102030405060708090100
U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Watermg/mLDraw
0.5 mL20—
1 mL10—
1.5 mL6.667—
2 mL5—
2.5 mL4—
3 mL3.333—
5 mL2—

Supplies and handling

  • Lyophilized vial
    Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
  • Sterile diluent
    The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
  • Graduated syringes
    Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
  • Alcohol prep pads
    For wiping vial stoppers before each puncture.
  • Nitrile gloves
    Clean gloves for aseptic handling.
  • Sharps container
    Puncture-resistant container for used needles.
Step-by-step reconstitution guideStorage and transport accessories

Storage

No approved-product storage instructions exist. In one study a nasal-spray formulation was stable for up to 60 days at 4 degrees C 8; otherwise handling should follow the supplier's documentation.

  • Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
  • Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
  • Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent
The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed
Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles
Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution
This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed
Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status
Not approved by the FDA or, in the sources reviewed, any other regulator. A Drugs@FDA / openFDA query for kisspeptin returned no application record 9. Kisspeptin-54 is not named in FDA's May 14, 2026 503A bulk substances list, where kisspeptin-10 is in category 2 (significant safety risks) 10. Human studies have been academic, investigator-led trials 5,7.
United States (FDA)
Not approved. A Drugs@FDA / openFDA query for kisspeptin returns no matching applications 9. Kisspeptin-54 is not named in FDA's May 14, 2026 503A bulk substances list; kisspeptin-10 is listed in category 2 10.
Sport (WADA)
Prohibited at all times. Section S2.2.1, testosterone-stimulating peptides in males, names kisspeptin and its agonist analogues 12.

Status varies by country and changes over time. How we describe regulatory status.

Kisspeptin-54 compared with related compounds

CompoundStatusEvidenceHuman amountsHalf-life
Kisspeptin-54Not approved — research use onlyBNone establishedAbout 28 minutes (intravenous, healthy m
Kisspeptin-10Not approved — research use onlyBNone established—
GonadorelinApproved, no longer marketedBLabel not retrievableA review describes native GnRH as having
PEANot approved — research use onlyANone established—
NAD+Not approved — research use onlyBNone established—
Apelin-13Not approved — research use onlyBNone establishedNot located as a numeric value in the so

Frequently asked questions

What doses of Kisspeptin-54 have been studied in humans?
None that establish an amount. Kisspeptin-54 is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.
Is there an established Kisspeptin-54 cycle length?
No cycle length or break has been established. Human studies administered Kisspeptin-54 for the periods listed on this page; those are study durations, not a recommended course.
How much bacteriostatic water should be added to a Kisspeptin-54 vial?
There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.
How many units is a given amount on an insulin syringe?
On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.
What is the half-life of Kisspeptin-54?
About 28 minutes (intravenous, healthy men)
Is Kisspeptin-54 FDA-approved?
Not approved — research use only. Not approved by the FDA or, in the sources reviewed, any other regulator. A Drugs@FDA / openFDA query for kisspeptin returned no application record 9. Kisspeptin-54 is not named in FDA's May 14, 2026 503A bulk substances list, where kisspeptin-10 is in category 2 (significant safety risks) 10. Human studies have been academic, investigator-led trials 5,7.

References

  1. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males J Clin Endocrinol Metab. 2005
  2. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women J Clin Endocrinol Metab. 2007
  3. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis J Clin Endocrinol Metab. 2009
  4. Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers J Clin Endocrinol Metab. 2013
  5. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization J Clin Invest. 2014
  6. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy J Clin Endocrinol Metab. 2015
  7. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial Hum Reprod. 2017
  8. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans EBioMedicine. 2025
  9. Drugs@FDA application data queried through openFDA for kisspeptin (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  10. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (categories 1, 2 and 3; updated May 14, 2026) FDA. 2026
  11. PubChem compound record for kisspeptin (kisspeptin-54, metastin) (CID 71306396; CAS 388138-21-4) PubChem. 2026
  12. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026

Last reviewed October 23, 2026 by the Amiravo editorial team. Editorial policy · Report an error